Physician profile
Raya Massoud
NPI 1831370063
$774.64
in general payments reported to CMS, 2019-2025
24 companies · $64.85 in 2025
The $64.85 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.02 · 2020: $44.63 · 2021: $218 · 2022: $96.85 · 2023: $223 · 2024: $70.14 · 2025: $64.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $94.85 | 2022-2023 | |
| Amgen INC. | $94.79 | 2019-2022 | |
| Genentech USA, INC. | $52.61 | 2023 | Ocrevus |
| Merck Sharp & Dohme LLC | $46.63 | 2021-2023 | Keytruda |
| Supernus Pharmaceuticals, INC. | $43.06 | 2019 | |
| Life Molecular Imaging Ltd | $42.59 | 2025 | Neuraceq |
| Janssen Biotech, INC. | $39.93 | 2021-2024 | Imbruvica, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $27.70 | 2021 | |
| Alnylam Pharmaceuticals INC. | $25.39 | 2021 | |
| Exelixis INC. | $25.32 | 2024 | Cabometyx |
| Astrazeneca Pharmaceuticals Lp | $24.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.26 | 2024 | Xarelto |
| Karyopharm Therapeutics INC. | $22.54 | 2023 | Xpovio |
| Mirati Therapeutics, INC. | $22.50 | 2023 | Krazati |
| Lilly USA, LLC | $22.26 | 2025 | Emgality |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $21.70 | 2022 | |
| Morphosys, US INC. | $21.61 | 2021 | |
| Pfizer INC. | $20.03 | 2021 | |
| Abbvie INC. | $19.32 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $18.37 | 2020 | |
| Pharming Healthcare, INC. | $17.94 | 2023 | Ruconest |
| Seagen INC. | $16.98 | 2021 | |
| Clovis Oncology, INC. | $16.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raya Massoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.